Abstract:Dyslipidemia plays a role of significant risk factor for development and progression of cardiovascular diseases. Today several classes of hypolipemic drugs with evidenced effectiveness are used. But some patients don’t tolerate medicines with high efficacy or can’t achieve the targeted blood lipid profile levels even in case of the use of maximal doses or combined therapy. This necessitates the creation of new hypolipidemic agents. The review is devoted to discussion of new directions of influence on impaired lipid metabolism through creation of new classes of hypolipemic drugs with some perspectives of effective correction of lipid factors of cardiovascular risk (CVR) in cases of impossibility to achieve the targeted levels of low‐density lipoprotein cholesterol (LDL‐C) or there is a residual CVR caused by elevated serum triglyceride (TG) levels and/or low levels of high‐density lipoprotein cholesterol (HDL‐C). Among the novel drugs for hypercholesterolemia (HCE) correction, considerations are given for some mechanisms of action and efficacy of application of proprotein convertase subtilisin‐kexine type 9 (PCSK9) inhibitors as well as bempedoic acid (adenosine triphosphate citrate lyase inhibitor) and inclisiran, a small synthesized interfering ribonucleic acid (RNA) with its ability to blockade genes‐regulators of hepatic PCSK9 activity. The novel agents for hypertriglyceridemia correction, discussed in the review, include icosapent ethyl (a high purified and firm ester of ethyl‐eicosapentoenic acid), pemafibrate (the first selective modulator of α‐receptors activated by peroxisome proliferator), apolipoprotein C‐III (ApoC‐III) inhibitors (volasenorsen, olesarsen), mipomersen (antisense nucleotide for matrix RNA of apolipoprotein B‐100), lomitapide (inhibitor of microsomal TG transfer protein) and inhibitors of angiopoietin‐like protein 3 (ANGPTL3) (evinacumab, vupanorsen). Among the new approaches to HDL‐C elevation an attention is paid to the experimental and clinical investigations of recombinant HDL, agents with recombinant lecithin‐cholesterol‐acyl‐transferase (LCAT), and apolipoprotein A‐I (ApoA‐I) mimetic peptides. For the lowering of blood lipoprotein(a) (LP(a)) level the possibilities of pelacarsen, an antisense oligonucleotide for matrix RNA of apolipoprotein(a) (apo(a)) contained in LP(a) molecule and olpasiran, a small interfering RNA for LP(a) molecule inhibited apo(a) synthesis are uncovered. A high probability of clinical application in the nearest future will have novel drugs approved by US Food and Drug Administration (FDA) and European Medicines Agency (EMA) such as bempedoic acid and inclisiran for HCE correction as well as lomitapide for the treatment of familial HCE.

Hypolipidemic Effects of β-Glucans, Mannans, and Fucoidans: Mechanism of Action and Their Prospects for Clinical Application

Polysaccharides Derived from Natural Sources Regulate Triglyceride and Cholesterol Metabolism: a Review of the Mechanisms.

The Influence of Polysaccharides on Lipid Metabolism: Insights from Gut Microbiota

Polysaccharides derived from natural sources regulate lipid metabolism: A review of the mechanisms

β-Glucan Metabolic and Immunomodulatory Properties and Potential for Clinical Application

An Insight into Antihyperlipidemic Effects of Polysaccharides from Natural Resources

Lipid metabolism regulation by dietary polysaccharides with different structural properties

Effects of Oat Beta-Glucan Intake on Lipid Profiles in Hypercholesterolemic Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Efficacy of Food Industry By-Product β-Glucan/Chitin–Chitosan on Lipid Profile of Overweight and Obese Individuals: Sustainability and Nutraceuticals

Innovative Applications of Pectin in Lipid Management: Mechanisms, Modifications, Synergies, Nanocarrier Systems, and Safety Considerations

Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management

Hypolipidemic activity of phytochemical combinations: A mechanistic review of preclinical and clinical studies

Ganoderma lucidum polysaccharides improve lipid metabolism against high-fat diet-induced dyslipidemia

Exploring the Hypocholesterolemic Potential of a Fucus vesiculosus Extract: Omic Insights into Molecular Mechanisms at the Intestinal Level

Effects of Different Delivering Matrices of Β-Glucan on Lipids in Mildly Hypercholesterolaemic Individuals: a Meta-Analysis of Randomised Controlled Trials

Utilization of Food-Derived β-Glucans to Prevent and Treat Non-Alcoholic Fatty Liver Disease (NAFLD)

Two Laminaria Japonica Polysaccharides with Distinct Structure Characterization Affect Gut Microbiota and Metabolites in Hyperlipidemic Mice Differently.

The effects of cereal β-glucans on cardiovascular risk factors and the role of the gut microbiome

Polysaccharide Structures and Their Hypocholesterolemic Potential

Contemporary hypolipemic therapy: possibilities of novel hypolipemic drugs in correction of lipid metabolism disorders. Review

Hypolipidemic effect of brown seaweed (Sargassum crassifolium) extract in vivo (Study of histopathology, mRNA expression, and immunohistochemistry (IHC) with VCAM-1, ICAM-1, and MCP-1 parameters)